CorMedix gets FDA nod to begin clinical trial for Neutrolin
The IND was based on a pivotal Phase III protocol for Neutrolin in hemodialysis patients with a central venous catheter. The multi-center, randomized, controlled Phase III clinical trial
XtalPi has entered a strategic partnership valued at more than $400m with an international biopharmaceutical company to develop oral small-molecule therapeutics targeting a G protein-coupled receptor (GPCR).
Over the past seven months, Mersana and Takeda have been conducting pre-clinical, proof-of-concept studies for several Fleximer-ADCs against an undisclosed oncology target under a research license to Mersana’s
XTEN is Amunix’s proprietary protein-based polymer that mimics the biophysical properties of PEG and is used to extend the half-life of genetically fused therapeutic proteins and peptides. "We